B-cell responses after intranasal vaccination with the novel attenuated Bordetella pertussis vaccine strain BPZE1 in a randomized phase I clinical trial

Vaccine

Volumn 32, Issue 27, 2014, Pages 3350-3356

  Jahnmatz, Maja ^a,b   Amu, Sylvie ^b   Ljungman, Margaretha ^a   Wehlin, Lena ^a   Chiodi, Francesca ^b   Mielcarek, Nathalie ^c,d   Locht, Camille ^c,d   Thorstensson, Rigmor ^a  

^a SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c INSERM U1019   (France)

^d UNIV LILLE   (France)

Author keywords

B cells; BPZE1; Live attenuated nasal vaccine; Novel human vaccine; Pertussis; Phase I clinical trial

Indexed keywords

HEMAGGLUTININ; IMMUNOGLOBULIN G; PERTACTIN; PERTUSSIS TOXIN; PERTUSSIS VACCINE; PLACEBO; BACTERIUM ANTIBODY; LIVE VACCINE;

ADULT; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL SHEDDING; BACTERIAL STRAIN; BACTERIUM CULTURE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN; HUMAN CELL; IMMUNOGLOBULIN BLOOD LEVEL; MALE; MEMORY CELL; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PERTUSSIS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VACCINATION; ANTIBODY PRODUCTION; B LYMPHOCYTE; BLOOD; BORDETELLA PERTUSSIS; CLINICAL TRIAL; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; INTRANASAL DRUG ADMINISTRATION; PLASMA CELL; WHOOPING COUGH;

ADMINISTRATION, INTRANASAL; ADULT; ANTIBODIES, BACTERIAL; ANTIBODY FORMATION; B-LYMPHOCYTE SUBSETS; B-LYMPHOCYTES; BORDETELLA PERTUSSIS; HUMANS; IMMUNOGLOBULIN G; IMMUNOLOGIC MEMORY; MALE; PERTUSSIS VACCINE; PLASMA CELLS; VACCINES, ATTENUATED; WHOOPING COUGH;

EID: 84901016516     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.04.048     Document Type: Article

References (35)

1. WHO Pertussis vaccines: WHO position paper. Wkly Epidemiol Rec 2010, 85:385-400.
2. Pebody R.G., Gay N.J., Giammanco A., Baron S., Schellekens J., Tischer A., et al. The seroepidemiology of Bordetella pertussis infection in Western Europe. Epidemiol Infect 2005, 133:159-171.
3. White O.J., Rowe J., Richmond P., Marshall H., McIntyre P., Wood N., et al. Th2-polarisation of cellular immune memory to neonatal pertussis vaccination. Vaccine 2010, 28:2648-2652.
4. Gentile A., Bhutta Z., Bravo L., Samy A.G., Garcia R.D., Hoosen A., et al. Pediatric disease burden and vaccination recommendations: understanding local differences. Int J Infect Dis 2010, 14:e649-e658.
5. Bisgard K.M., Pascual F.B., Ehresmann K.R., Miller C.A., Cianfrini C., Jennings C.E., et al. Infant pertussis: who was the source. Pediatr Infect Dis J 2004, 23:985-989.
6. Mascart F., Verscheure V., Malfroot A., Hainaut M., Pierard D., Temerman S., et al. Bordetella pertussis infection in 2-month-old infants promotes type 1T cell responses. J Immunol (Baltimore, Md: 1950) 2003, 170:1504-1509.
7. Ryan M., Murphy G., Gothefors L., Nilsson L., Storsaeter J., Mills K.H. Bordetella pertussis respiratory infection in children is associated with preferential activation of type 1T helper cells. J Infect Dis 1997, 175:1246-1250.
8. Leef M., Elkins K.L., Barbic J., Shahin R.D. Protective immunity to Bordetella pertussis requires both B cells and CD4(+) T cells for key functions other than specific antibody production. J Exp Med 2000, 191:1841-1852.
9. Mahon B.P., Brady M.T., Mills K.H. Protection against Bordetella pertussis in mice in the absence of detectable circulating antibody: implications for long-term immunity in children. J Infect Dis 2000, 181:2087-2091.
10. Ausiello C.M., Urbani F., la Sala A., Lande R., Cassone A. Vaccine- and antigen-dependent type 1 and type 2 cytokine induction after primary vaccination of infants with whole-cell or acellular pertussis vaccines. Infect Immun 1997, 65:2168-2174.
11. Ryan M., Murphy G., Ryan E., Nilsson L., Shackley F., Gothefors L., et al. Distinct T-cell subtypes induced with whole cell and acellular pertussis vaccines in children. Immunology 1998, 93:1-10.
12. Mielcarek N., Debrie A.S., Raze D., Bertout J., Rouanet C., Younes A.B., et al. Live attenuated B. pertussis as a single-dose nasal vaccine against whooping cough. PLoS Pathog 2006, 2:e65.
13. Feunou P.F., Ismaili J., Debrie A.S., Huot L., Hot D., Raze D., et al. Genetic stability of the live attenuated Bordetella pertussis vaccine candidate BPZE1. Vaccine 2008, 26:5722-5727.
14. Feunou P.F., Bertout J., Locht C. T- and B-cell-mediated protection induced by novel, live attenuated pertussis vaccine in mice. Cross protection against parapertussis. PLoS ONE 2010, 5:e10178.
15. Skerry C.M., Mahon B.P. A live, attenuated Bordetella pertussis vaccine provides long-term protection against virulent challenge in a murine model. Clin Vacc Immunol: CVI 2011, 18:187-193.
16. Thorstensson R., Trollfors B., Al-Tawil N., Jahnmatz M., Bergstrom J., Ljungman M., et al. A phase I clinical study of a live attenuated Bordetella pertussis vaccine - BPZE1; a single centre, double-blind, placebo-controlled, dose-escalating study of BPZE1 given intranasally to healthy adult male volunteers. PLoS ONE 2014, 9:e83449.
17. Nilsson C., Aboud S., Karlen K., Hejdeman B., Urassa W., Biberfeld G. Optimal blood mononuclear cell isolation procedures for gamma interferon enzyme-linked immunospot testing of healthy Swedish and Tanzanian subjects. Clin Vacc Immunol: CVI 2008, 15:585-589.
18. Jahnmatz M., Kesa G., Netterlid E., Buisman A.M., Thorstensson R., Ahlborg N. Optimization of a human IgG B-cell ELISpot assay for the analysis of vaccine-induced B-cell responses. J Immunol Methods 2013, 391:50-59.
19. Mielcarek N., Debrie A.S., Mahieux S., Locht C. Dose response of attenuated Bordetella pertussis BPZE1-induced protection in mice. Clin Vacc Immunol: CVI 2010, 17:317-324.
20. Blanchard-Rohner G., Pulickal A.S., Jol-van der Zijde C.M., Snape M.D., Pollard A.J. Appearance of peripheral blood plasma cells and memory B cells in a primary and secondary immune response in humans. Blood 2009, 114:4998-5002.
21. Mamani-Matsuda M., Cosma A., Weller S., Faili A., Staib C., Garcon L., et al. The human spleen is a major reservoir for long-lived vaccinia virus-specific memory B cells. Blood 2008, 111:4653-4659.
22. Perez-Andres M., Paiva B., Nieto W.G., Caraux A., Schmitz A., Almeida J., et al. Human peripheral blood B-cell compartments: a crossroad in B-cell traffic. Cytometry B Clin Cytom 2010, 78(Suppl. 1):S47-S60.
23. Blink E.J., Light A., Kallies A., Nutt S.L., Hodgkin P.D., Tarlinton D.M. Early appearance of germinal center-derived memory B cells and plasma cells in blood after primary immunization. J Exp Med 2005, 201:545-554.
24. Ramirez K., Wahid R., Richardson C., Bargatze R.F., El-Kamary S.S., Sztein M.B., et al. Intranasal vaccination with an adjuvanted Norwalk virus-like particle vaccine elicits antigen-specific B memory responses in human adult volunteers. Clin Immunol (Orlando, Fla) 2012, 144:98-108.
25. Hendrikx L.H., Felderhof M.K., Ozturk K., de Rond L.G., van Houten M.A., Sanders E.A., et al. Enhanced memory B-cell immune responses after a second acellular pertussis booster vaccination in children 9 years of age. Vaccine 2011, 30:51-58.
26. Nanan R., Heinrich D., Frosch M., Kreth H.W. Acute and long-term effects of booster immunisation on frequencies of antigen-specific memory B-lymphocytes. Vaccine 2001, 20:498-504.
27. Schure R.M., Hendrikx L.H., de Rond L.G., Ozturk K., Sanders E.A., Berbers G.A., et al. Differential T- and B-cell responses to pertussis in acellular vaccine-primed versus whole-cell vaccine-primed children 2 years after preschool acellular booster vaccination. Clin Vacc Immunol: CVI 2013, 20:1388-1395.
28. Moir S., Ho J., Malaspina A., Wang W., DiPoto A.C., O'Shea M.A., et al. Evidence for HIV-associated B cell exhaustion in a dysfunctional memory B cell compartment in HIV-infected viremic individuals. J Exp Med 2008, 205:1797-1805.
29. CDC Pertussis epidemic - Washington, 2012. MMWR Morb Mort Wkly Rep 2012, 61:517-522.
30. Liko J., Robison S.G., Cieslak P.R. Priming with whole-cell versus acellular pertussis vaccine. N Engl J Med 2013, 368:581-582.
31. Sheridan S.L., Ware R.S., Grimwood K., Lambert S.B. Number and order of whole cell pertussis vaccines in infancy and disease protection. JAMA 2012, 308:454-456.
32. Witt M.A., Arias L., Katz P.H., Truong E.T., Witt D.J. Reduced risk of pertussis among persons ever vaccinated with whole cell pertussis vaccine compared to recipients of acellular pertussis vaccines in a large US cohort. Clin Infect Dis Off Publ Infect Dis Soc Am 2013, 56:1248-1254.
33. Feunou P.F., Kammoun H., Debrie A.S., Mielcarek N., Locht C. Long-term immunity against pertussis induced by a single nasal administration of live attenuated B. pertussis BPZE1. Vaccine 2010, 28:7047-7053.
34. Siegrist C.A. The challenges of vaccine responses in early life: selected examples. J Comp Pathol 2007, 137(Suppl. 1):S4-S9.
35. + T cells in infants compared to adults following DTaP vaccination. Clin Exp Immunol 2012, 169:281-291.